Long-term Outcomes of Combined Hepatocellular-Cholangiocarcinoma after Hepatectomy or Liver Transplantation: A Systematic Review and Meta-Analysis.

De-Bang Li,Xiao-Ying Si,Shi-Jie Wang,Yan-Ming Zhou
DOI: https://doi.org/10.1016/j.hbpd.2018.10.001
IF: 3.355
2019-01-01
Hepatobiliary & Pancreatic Diseases International
Abstract:Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy. We conducted a systematic review and meta-analysis to assess the evidence available on the long-term outcomes of cHCC-CC patients after either hepatectomy or liver transplantation (LT). Data Sources: Relevant studies published between January 20 0 0 and January 2018 were identified by searching PubMed and Embase and reviewed systematically. Data were pooled using a random-effects model. Results: A total of 42 observational studies involving 1691 patients (1390 for partial hepatectomy and 301 for LT) were included in the analysis. The median tumor recurrence and 5-year overall survival (OS) rates were 65% (range 38%-100%) and 29% (range 0-63%) after hepatectomy versus 54% (range 14%-93%) and 41% (range 16%-73%) after LT, respectively. Meta-analysis found no significant difference in OS and tumor recurrence between LT and hepatectomy groups. Conclusion: Hepatectomy rather than LT should be considered as the prior treatment option for cHCC-CC. (C) 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?